Atorvastatin vs Ezetimibe: What to Choose and for Whom
Atorvastatin and ezetimibe are rarely genuine “competitors”: in most clinical situations the question is not “which of the two” but “which to start with and when to add the second.” The editorial team explains how doctors build lipid-lowering therapy according to current guidelines, for whom ezetimibe may become the main drug and what is important to know for people who train regularly.
The goal of treatment: LDL target by risk
The starting point of any decision is overall cardiovascular risk. The European ESC/EAS 2019 guidelines link each risk category to a specific LDL target. The higher the risk, the lower the target should be and the more intensive the therapy will be.
| Risk category | Examples | LDL target |
|---|---|---|
| Very high | A previous heart attack, stroke, stenting; diabetes with organ damage | <1.4 mmol/L and a reduction of ≥50% from baseline |
| High | Familial hypercholesterolemia, LDL >4.9 mmol/L, long-standing diabetes | <1.8 mmol/L and a reduction of ≥50% |
| Moderate | Young people with diabetes without complications, moderate calculated risk | <2.6 mmol/L |
| Low | Low calculated risk by SCORE2 | <3.0 mmol/L |
Knowing the target and baseline LDL, the doctor assesses by what percentage the indicator needs to be lowered. If a reduction of 30–40% is needed, a moderate-intensity statin is usually enough. If 50% and more — a high-intensity statin is needed, and often a combination too.
This approach explains why a small dose of a statin is enough for one person, while another needs two drugs at maximally tolerated doses. Comparing your therapy with that of acquaintances without taking risk into account is incorrect.
It is also important to remember: the LDL target is not “optimal well-being” but a reduction in the probability of a heart attack and stroke in the future. High cholesterol is usually not felt in any way.
A statin as the first step
For the vast majority of patients the first drug is a statin — for example, atorvastatin. Its benefit for reducing cardiovascular events has been proven in many large studies, in particular ASCOT-LLA and TNT, and the CTT meta-analysis (2010) showed a stable relationship between lowering LDL and reducing risk.
Atorvastatin is convenient in that it covers both moderate and high intensity depending on the dose. The doctor chooses the starting dose by the required percentage of reduction, and after 6–8 weeks assesses the result with a lipid profile.
The first-line statin does not necessarily have to be atorvastatin: in a number of situations rosuvastatin is more appropriate, for example with many interactions via CYP3A4. However, the logic remains the same — first a statin at the maximally tolerated dose.
Starting therapy with ezetimibe on your own “because it is gentler” at high risk is unwarranted: for ezetimibe monotherapy there are no studies with hard endpoints, and the strength of LDL reduction is moderate.
When ezetimibe is added
The ESC/EAS 2019 guidelines recommend adding ezetimibe if, at the maximally tolerated dose of a statin, the LDL target is not reached. This is the most frequent and best-substantiated scenario: in the IMPROVE-IT study such a combination after acute coronary syndrome reduced the rate of cardiovascular events compared with a statin in monotherapy.
The strategy of early combination is attracting more and more attention — combining a moderate-intensity statin with ezetimibe instead of a high-intensity statin. In the RACING study (Kim et al., 2022), rosuvastatin 10 mg together with ezetimibe was no worse than rosuvastatin 20 mg regarding cardiovascular events, while discontinuation of therapy due to intolerance occurred less frequently. Although this study concerned rosuvastatin, it supports the very idea of a combined approach.
The combination is often produced as a single tablet, which improves adherence to treatment. For people who need an LDL reduction of 60% and more, it not uncommonly becomes the starting option.
If even the combination does not ensure the target, the next step is PCSK9 inhibitors or other modern drugs. This decision is made by a cardiologist or lipidologist.
Statin intolerance
Some patients complain of muscle symptoms against the background of statins. The EAS consensus (Stroes et al., 2015) recommends not abandoning statins immediately: first take a pause, then try the same drug again at a lower dose or a different statin, in particular with intake every other day.
True complete statin intolerance occurs less often than is said. However, if it is confirmed, ezetimibe becomes an important drug of choice: it is well tolerated and does not cause the muscle problems characteristic of statins.
In such cases, ezetimibe is often combined with the minimum tolerated dose of a statin — even a small dose provides additional benefit. If the target is unattainable, the doctor considers other agents.
- Do not stop taking a statin on your own because of muscle pain — discuss the symptoms with a doctor.
- Check your vitamin D level and thyroid function: hypothyroidism increases the risk of muscle complaints.
- Inform your doctor about all medications and supplements, especially those that affect CYP3A4.
Training and monitoring of tests
For physically active people it is important to distinguish the usual post-workout soreness from symptoms associated with a statin. The latter are more often symmetrical, affect the large muscles of the thighs and shoulders, and do not pass after a few days of rest.
Creatine kinase after heavy workouts can rise severalfold without any drugs. Therefore a baseline CK test before the start of a statin is better taken after several days without intense loads, and if myopathy is suspected — also after a pause in training.
People who use anabolic steroids often have a pronounced decrease in HDL and an increase in LDL. A statin or ezetimibe does not compensate for the other risks of such drugs — from myocardial hypertrophy to erythrocytosis — and the strategy of “covering” them with lipid-lowering agents is mistaken.
Standard monitoring of therapy includes a lipid profile 6–8 weeks after the start or a dose change, ALT before the start and as indicated, CK with muscle symptoms. Neither atorvastatin nor ezetimibe is on the WADA Prohibited List.
Editorial conclusions
For most people with indications for treatment, the first step is a statin, in particular atorvastatin, and ezetimibe is added if the LDL target is not reached.
Early combination of a moderate-intensity statin with ezetimibe is a modern alternative to high doses of statins, especially when a significant reduction in LDL is needed.
In confirmed statin intolerance, ezetimibe becomes a key drug, but for its monotherapy there are no data on reducing heart attacks and strokes.
We described the pharmacological differences in the article “Atorvastatin or Ezetimibe: What Is the Difference.” We also recommend “Rosuvastatin vs Citrus Bergamot: What to Choose and for Whom” and material on creatine kinase in athletes.
References
- Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188.
- Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–2397.
- Kim BK, Hong SJ, Lee YJ, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet. 2022;400(10349):380–390.
- LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425–1435.
- Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy — European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36(17):1012–1022.
- Cholesterol Treatment Trialists' (CTT) Collaboration; Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681.
- Pope HG Jr, Wood RI, Rogol A, et al. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014;35(3):341–375.
Andriy Melnyk
A strength-sports coach and author of programs for beginner and intermediate levels. Writes about training planning.
